Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics". - Bovijn J; Krebs K; Chen CY; Boxall R; Censin JC; Ferreira T; Pulit SL; Glastonbury CA; Laber S; Millwood IY; Lin K; Li L; et al. (Science translational medicine, 2021)